COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Artivion, Inc. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jun 26, 2026 to Jun 26, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QSK appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250055, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1655 Roberts Blvd. NW, Kennesaw, GA, 30144. Recorded on P250055, decision dated Jun 26, 2026.
Device categories in this collection
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment.
Changes described in PMA records
FDA’s recorded scope: The AMDS Hybrid Prosthesis is indicated for use in patients with acute DeBakey Type I aortic dissections with malperfusion (including cerebral, visceral, renal, and peripheral malperfusion) and a primary entry tear within the ascending aorta proximal to the innominate artery, who are undergoing open surgical repair within 0-14 days of diagnosis.
Jun 26, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.